Shinpei Kawaoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shinpei Kawaoka has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Yutaka Suzuki
Graduate School of Frontier Science, The University of Tokyo, Chiba 277-8562, Japan
8 shared publicationsRin Mizuno
Inter-Organ Communication Research Team, Institute for Life and Medical Sciences, Kyoto University , 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
7 shared publicationsMayuko Yoda
Department of Integrative Bioanalytics, Institute of Development, Aging and Cancer (IDAC), Tohoku University
6 shared publicationsRiyo Konishi
Inter-Organ Communication Research Team, Institute for Frontier Life and Medical Sciences
6 shared publicationsYuki Nakamura
Inter‐Organ Communication Research Team Institute for Life and Medical Sciences Kyoto Japan
5 shared publications- Yutaka Suzuki
The University of Tokyo
5 shared publications
Latest Publications
- 5 September 2025
- Published by MyJove Corporation
- No. 223,p. e68892
JoVE Video Dataset
Spatial transcriptomics is a rapidly evolving technology that enables the capture of gene expression patterns in tissue samples while preserving positional information. It has wide-ranging applications in biological research and bioinformatics, allowing researchers to investigate and track spatial variations in gene expression across different tissues, conditions, and diseases. With spatial transcriptomics data analysis gaining traction, the number of publicly available datasets is rising. However, spatial transcriptomics remains a highly specialized experimental technique, with significant technical and financial constraints. To facilitate access to spatial data, we have recently developed DeepSpaceDB, a comprehensive and dynamic database for spatial transcriptomics data exploration. This article presents detailed workflows outlining the components of the database and its navigation with the help of a few examples. First, the analysis of a mouse brain sample is demonstrated, exploring quality indicators, spatially variable genes and pathways, and gene expression variations between the hippocampus and hypothalamus. Next, the identification and annotation of differentially expressed genes associated with immune activity is further explored by comparing metastatic regions of colorectal origin with distant areas of healthy tissue in murine livers. DeepSpaceDB, with its advanced tools and interactive features, serves as a valuable resource for spatial transcriptomics research, enabling deeper exploration of tissue organization and disease biology.
- 5 September 2025
- Published by MyJove Corporation
- No. 223,p. e68892
JoVE Video Dataset
Spatial transcriptomics is a rapidly evolving technology that enables the capture of gene expression patterns in tissue samples while preserving positional information. It has wide-ranging applications in biological research and bioinformatics, allowing researchers to investigate and track spatial variations in gene expression across different tissues, conditions, and diseases. With spatial transcriptomics data analysis gaining traction, the number of publicly available datasets is rising. However, spatial transcriptomics remains a highly specialized experimental technique, with significant technical and financial constraints. To facilitate access to spatial data, we have recently developed DeepSpaceDB, a comprehensive and dynamic database for spatial transcriptomics data exploration. This article presents detailed workflows outlining the components of the database and its navigation with the help of a few examples. First, the analysis of a mouse brain sample is demonstrated, exploring quality indicators, spatially variable genes and pathways, and gene expression variations between the hippocampus and hypothalamus. Next, the identification and annotation of differentially expressed genes associated with immune activity is further explored by comparing metastatic regions of colorectal origin with distant areas of healthy tissue in murine livers. DeepSpaceDB, with its advanced tools and interactive features, serves as a valuable resource for spatial transcriptomics research, enabling deeper exploration of tissue organization and disease biology.
- 5 September 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 223,p. e68892
Mining Spatial Transcriptomics Datasets using DeepSpaceDB
Spatial transcriptomics is a rapidly evolving technology that enables the capture of gene expression patterns in tissue samples while preserving positional information. It has wide-ranging applications in biological research and bioinformatics, allowing researchers to investigate and track spatial variations in gene expression across different tissues, conditions, and diseases. With spatial transcriptomics data analysis gaining traction, the number of publicly available datasets is rising. However, spatial transcriptomics remains a highly specialized experimental technique, with significant technical and financial constraints. To facilitate access to spatial data, we have recently developed DeepSpaceDB, a comprehensive and dynamic database for spatial transcriptomics data exploration. This article presents detailed workflows outlining the components of the database and its navigation with the help of a few examples. First, the analysis of a mouse brain sample is demonstrated, exploring quality indicators, spatially variable genes and pathways, and gene expression variations between the hippocampus and hypothalamus. Next, the identification and annotation of differentially expressed genes associated with immune activity is further explored by comparing metastatic regions of colorectal origin with distant areas of healthy tissue in murine livers. DeepSpaceDB, with its advanced tools and interactive features, serves as a valuable resource for spatial transcriptomics research, enabling deeper exploration of tissue organization and disease biology.
- 5 September 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 223,p. e68892
Mining Spatial Transcriptomics Datasets using DeepSpaceDB
Spatial transcriptomics is a rapidly evolving technology that enables the capture of gene expression patterns in tissue samples while preserving positional information. It has wide-ranging applications in biological research and bioinformatics, allowing researchers to investigate and track spatial variations in gene expression across different tissues, conditions, and diseases. With spatial transcriptomics data analysis gaining traction, the number of publicly available datasets is rising. However, spatial transcriptomics remains a highly specialized experimental technique, with significant technical and financial constraints. To facilitate access to spatial data, we have recently developed DeepSpaceDB, a comprehensive and dynamic database for spatial transcriptomics data exploration. This article presents detailed workflows outlining the components of the database and its navigation with the help of a few examples. First, the analysis of a mouse brain sample is demonstrated, exploring quality indicators, spatially variable genes and pathways, and gene expression variations between the hippocampus and hypothalamus. Next, the identification and annotation of differentially expressed genes associated with immune activity is further explored by comparing metastatic regions of colorectal origin with distant areas of healthy tissue in murine livers. DeepSpaceDB, with its advanced tools and interactive features, serves as a valuable resource for spatial transcriptomics research, enabling deeper exploration of tissue organization and disease biology.
- Open Access
- 4 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7528
Plasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell Carcinoma
Cancer is a systemic disease rather than a localized pathology and is characterized by widespread effects, including whole-body exhaustion and chronic inflammation. A thorough understanding of cancer pathophysiology requires a systemic approach that accounts for the complex interactions between cancer cells and host tissues. To explore these dynamics, we employed a comprehensive metabolomic analysis of plasma samples from patients with either esophageal or head and neck squamous cell carcinoma (SCC). Plasma samples from 149 patients were metabolically profiled and correlated with clinical data. Among the metabolites identified, lysophosphatidylcholine (LPC) emerged as the sole biomarker strongly correlated with prognosis. A significant reduction in plasma LPC levels was linked to poorer overall survival. Plasma LPC levels demonstrated minimal correlation with patient-specific factors, such as tumor size and general condition, but showed significant association with the response to immune checkpoint inhibitor therapy. Proteomic and cytokine analyses revealed that low plasma LPC levels reflected systemic chronic inflammation, characterized by high levels of inflammatory proteins, the cytokines interleukin-6 and tumor necrosis factor-α, and coagulation-related proteins. These findings indicate that plasma LPC levels may be used as reliable biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in patients with SCC.
- 4 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7528
Open AccessPlasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell Carcinoma
Cancer is a systemic disease rather than a localized pathology and is characterized by widespread effects, including whole-body exhaustion and chronic inflammation. A thorough understanding of cancer pathophysiology requires a systemic approach that accounts for the complex interactions between cancer cells and host tissues. To explore these dynamics, we employed a comprehensive metabolomic analysis of plasma samples from patients with either esophageal or head and neck squamous cell carcinoma (SCC). Plasma samples from 149 patients were metabolically profiled and correlated with clinical data. Among the metabolites identified, lysophosphatidylcholine (LPC) emerged as the sole biomarker strongly correlated with prognosis. A significant reduction in plasma LPC levels was linked to poorer overall survival. Plasma LPC levels demonstrated minimal correlation with patient-specific factors, such as tumor size and general condition, but showed significant association with the response to immune checkpoint inhibitor therapy. Proteomic and cytokine analyses revealed that low plasma LPC levels reflected systemic chronic inflammation, characterized by high levels of inflammatory proteins, the cytokines interleukin-6 and tumor necrosis factor-α, and coagulation-related proteins. These findings indicate that plasma LPC levels may be used as reliable biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in patients with SCC.
- Open Access
- 15 November 2024
- Published by Springer Nature
- p. 231-273
Multidisciplinary Investigation on How Avatars and Devices Affect Human Physiology
The development of Cybernetic Avatars (CAs) will change our lives dramatically. Such a rapid evolution of new technologies is advantageous but also raises concerns, such as addiction. Herein, we present a new scientific issue regarding how to investigate the effects that using CAs throughout our lives has on our physiology. In this chapter, we discuss how avatars and devices affect human physiology at multiple levels, from gene expression to brain activity. We insist that our multidisciplinary investigation of how CAs affect us will be critical for the further development of our CA society.
- 15 November 2024
- Published by Springer Nature
- p. 231-273
Open AccessMultidisciplinary Investigation on How Avatars and Devices Affect Human Physiology
The development of Cybernetic Avatars (CAs) will change our lives dramatically. Such a rapid evolution of new technologies is advantageous but also raises concerns, such as addiction. Herein, we present a new scientific issue regarding how to investigate the effects that using CAs throughout our lives has on our physiology. In this chapter, we discuss how avatars and devices affect human physiology at multiple levels, from gene expression to brain activity. We insist that our multidisciplinary investigation of how CAs affect us will be critical for the further development of our CA society.
- Open Access
- 23 August 2024
- Published by Elsevier in EBioMedicine
- Vol. 107, 105271
Intra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals the reduction of CD169+ macrophages by metastatic breast cancers
- 23 August 2024
- Published by Elsevier in EBioMedicine
- Vol. 107, 105271
Open AccessIntra-patient spatial comparison of non-metastatic and metastatic lymph nodes reveals the reduction of CD169+ macrophages by metastatic breast cancers
- 5 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6704) , eadd8394
An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases
Transcribed enhancer maps can reveal nuclear interactions underpinning each cell type and connect specific cell types to diseases. Using a 5′ single-cell RNA sequencing approach, we defined transcription start sites of enhancer RNAs and other classes of coding and noncoding RNAs in human CD4 + T cells, revealing cellular heterogeneity and differentiation trajectories. Integration of these datasets with single-cell chromatin profiles showed that active enhancers with bidirectional RNA transcription are highly cell type–specific and that disease heritability is strongly enriched in these enhancers. The resulting cell type–resolved multimodal atlas of bidirectionally transcribed enhancers, which we linked with promoters using fine-scale chromatin contact maps, enabled us to systematically interpret genetic variants associated with a range of immune-mediated diseases.
- 5 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 385 (6704) , eadd8394
An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases
Transcribed enhancer maps can reveal nuclear interactions underpinning each cell type and connect specific cell types to diseases. Using a 5′ single-cell RNA sequencing approach, we defined transcription start sites of enhancer RNAs and other classes of coding and noncoding RNAs in human CD4 + T cells, revealing cellular heterogeneity and differentiation trajectories. Integration of these datasets with single-cell chromatin profiles showed that active enhancers with bidirectional RNA transcription are highly cell type–specific and that disease heritability is strongly enriched in these enhancers. The resulting cell type–resolved multimodal atlas of bidirectionally transcribed enhancers, which we linked with promoters using fine-scale chromatin contact maps, enabled us to systematically interpret genetic variants associated with a range of immune-mediated diseases.
- Open Access
- 22 January 2024
- Published by Wiley in Cancer Science
- Vol. 115 (3) , 715-722
Progressive, multi‐organ, and multi‐layered nature of cancer cachexia
Cancer cachexia is a complex, multifaceted condition that negatively impacts the health, treatment efficacy, and economic status of cancer patients. The management of cancer cachexia is an essential clinical need. Cancer cachexia is currently defined mainly according to the severity of weight loss and sarcopenia (i.e., macrosymptoms). However, such macrosymptoms may be insufficient to give clinicians clues on how to manage this condition as these symptoms appear at the late stage of cancer. We need to understand earlier events during the progression of cancer cachexia so as not to miss a clinical opportunity to control this complex syndrome. Recent research indicates that cancer‐induced changes in the host are much wider than previously recognized, including disruption of liver function and the immune system. Furthermore, such changes are observed before the occurrence of visible distant metastases (i.e., in early, localized cancers). In light of these findings, we propose to expand the definition of cancer cachexia to include all cancer‐induced changes to host physiology, including changes caused by early, localized cancers. This new definition of cancer cachexia can provide a new perspective on this topic, which can stimulate the research and development of novel cancer cachexia therapies.
- 22 January 2024
- Published by Wiley in Cancer Science
- Vol. 115 (3) , 715-722
Open AccessProgressive, multi‐organ, and multi‐layered nature of cancer cachexia
Cancer cachexia is a complex, multifaceted condition that negatively impacts the health, treatment efficacy, and economic status of cancer patients. The management of cancer cachexia is an essential clinical need. Cancer cachexia is currently defined mainly according to the severity of weight loss and sarcopenia (i.e., macrosymptoms). However, such macrosymptoms may be insufficient to give clinicians clues on how to manage this condition as these symptoms appear at the late stage of cancer. We need to understand earlier events during the progression of cancer cachexia so as not to miss a clinical opportunity to control this complex syndrome. Recent research indicates that cancer‐induced changes in the host are much wider than previously recognized, including disruption of liver function and the immune system. Furthermore, such changes are observed before the occurrence of visible distant metastases (i.e., in early, localized cancers). In light of these findings, we propose to expand the definition of cancer cachexia to include all cancer‐induced changes to host physiology, including changes caused by early, localized cancers. This new definition of cancer cachexia can provide a new perspective on this topic, which can stimulate the research and development of novel cancer cachexia therapies.
- Open Access
Low albumin status accompanies multi-layered immunosuppressive phenotypes in metastatic breast cancer patients
Low albumin status is prevalent in advanced cancer patients, but the pathophysiology associated with this anomaly remains largely unexplored. To address this, we aim to search correlations of albumin levels with the transcriptome against peripheral blood mononuclear cells and the plasma metabolome within the same patients having metastatic breast cancers. We confirm that metastatic breast cancer patients exhibit low albumin levels in varying degrees without prominent systemic inflammation. Our data demonstrate that low albumin levels correlate with transcriptome signatures indicative of “neutrophil activation and T-cell down-regulation,” an immunosuppressive phenotype. We also find that immunoregulatory metabolites, such as arginine, are reduced in plasma in an albumin-correlated manner, further corroborating systemic immunosuppression. These results are verified using a mouse model of breast cancer. We conclude that low albumin status in metastatic breast cancer patients accompanies immunosuppressive phenotypes, which is likely unfavorable for anti-cancer immunotherapy and thus can be a cause of unsuccessful treatment outcomes.
Open AccessLow albumin status accompanies multi-layered immunosuppressive phenotypes in metastatic breast cancer patients
Low albumin status is prevalent in advanced cancer patients, but the pathophysiology associated with this anomaly remains largely unexplored. To address this, we aim to search correlations of albumin levels with the transcriptome against peripheral blood mononuclear cells and the plasma metabolome within the same patients having metastatic breast cancers. We confirm that metastatic breast cancer patients exhibit low albumin levels in varying degrees without prominent systemic inflammation. Our data demonstrate that low albumin levels correlate with transcriptome signatures indicative of “neutrophil activation and T-cell down-regulation,” an immunosuppressive phenotype. We also find that immunoregulatory metabolites, such as arginine, are reduced in plasma in an albumin-correlated manner, further corroborating systemic immunosuppression. These results are verified using a mouse model of breast cancer. We conclude that low albumin status in metastatic breast cancer patients accompanies immunosuppressive phenotypes, which is likely unfavorable for anti-cancer immunotherapy and thus can be a cause of unsuccessful treatment outcomes.
- 4 April 2023
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 174 (1) , 89-98
Nicotinamide-N-methyltransferase regulates lipid metabolism via SAM and 1-methylnicotinamide in the AML12 hepatocyte cell line
Nicotinamide-N-methyltransferase (NNMT) is an enzyme that consumes S-adenosyl-methionine (SAM) and nicotinamide (NAM) to produce S-adenosyl-homocysteine (SAH) and 1-methylnicotinamide (MNAM). How much NNMT contributes to the quantity regulation of these four metabolites depends on whether NNMT is a major consumer or producer of these metabolites, which varies among various cellular contexts. Yet, whether NNMT critically regulates these metabolites in the AML12 hepatocyte cell line has been unexplored. To address this, we knock down Nnmt in AML12 cells and investigate the effects of Nnmt RNAi on metabolism and gene expression. We find that Nnmt RNAi accumulates SAM and SAH, whereas it reduces MNAM with NAM being unaltered. These results indicate that NNMT is a significant consumer of SAM and critical for MNAM production in this cell line. Moreover, transcriptome analyses reveal that altered SAM and MNAM homeostasis is accompanied by various detrimental molecular phenotypes, as exemplified by the down-regulations of lipogenic genes such as Srebf1. Consistent with this, oil-red O-staining experiments demonstrate the decrease of total neutral lipids upon Nnmt RNAi. Treating Nnmt RNAi AML12 cells with cycloleucine, an inhibitor of SAM biogenesis suppresses SAM accumulation and rescues the decrease of neutral lipids. MNAM also shows activity to elevate neutral lipids. These results suggest that NNMT contributes to lipid metabolism by maintaining proper SAM and MNAM homeostasis. This study provides an additional example where NNMT plays a critical role in regulating SAM and MNAM metabolism.
- 4 April 2023
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 174 (1) , 89-98
Nicotinamide-N-methyltransferase regulates lipid metabolism via SAM and 1-methylnicotinamide in the AML12 hepatocyte cell line
Nicotinamide-N-methyltransferase (NNMT) is an enzyme that consumes S-adenosyl-methionine (SAM) and nicotinamide (NAM) to produce S-adenosyl-homocysteine (SAH) and 1-methylnicotinamide (MNAM). How much NNMT contributes to the quantity regulation of these four metabolites depends on whether NNMT is a major consumer or producer of these metabolites, which varies among various cellular contexts. Yet, whether NNMT critically regulates these metabolites in the AML12 hepatocyte cell line has been unexplored. To address this, we knock down Nnmt in AML12 cells and investigate the effects of Nnmt RNAi on metabolism and gene expression. We find that Nnmt RNAi accumulates SAM and SAH, whereas it reduces MNAM with NAM being unaltered. These results indicate that NNMT is a significant consumer of SAM and critical for MNAM production in this cell line. Moreover, transcriptome analyses reveal that altered SAM and MNAM homeostasis is accompanied by various detrimental molecular phenotypes, as exemplified by the down-regulations of lipogenic genes such as Srebf1. Consistent with this, oil-red O-staining experiments demonstrate the decrease of total neutral lipids upon Nnmt RNAi. Treating Nnmt RNAi AML12 cells with cycloleucine, an inhibitor of SAM biogenesis suppresses SAM accumulation and rescues the decrease of neutral lipids. MNAM also shows activity to elevate neutral lipids. These results suggest that NNMT contributes to lipid metabolism by maintaining proper SAM and MNAM homeostasis. This study provides an additional example where NNMT plays a critical role in regulating SAM and MNAM metabolism.
- Open Access
- 3 February 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1097788
Serum amyloid alpha 1-2 are not required for liver inflammation in the 4T1 murine breast cancer model
Cancers induce the production of acute phase proteins such as serum amyloid alpha (SAA) in the liver and cause inflammation in various host organs. Despite the well-known coincidence of acute phase response and inflammation, the direct roles of SAA proteins in inflammation in the cancer context remains incompletely characterized, particularly in vivo. Here, we investigate the in vivo significance of SAA proteins in liver inflammation in the 4T1 murine breast cancer model. 4T1 cancers elevate the expression of SAA1 and SAA2, the two major murine acute phase proteins in the liver. The elevation of Saa1-2 correlates with the up-regulation of immune cell-related genes including neutrophil markers. To examine this correlation in detail, we generate mice that lack Saa1-2 and investigate immune-cell phenotypes. RNA-seq experiments reveal that deletion of Saa1-2 does not strongly affect 4T1-induced activation of immune cell-related genes in the liver. Flow cytometry experiments demonstrate the dispensable roles of SAA1-2 in cancer-dependent neutrophil infiltration to the liver. Consistently, 4T1-induced gene expression changes in bone marrow do not require Saa1-2. This study clarifies the negligible contribution of SAA1-2 proteins in liver inflammation in the 4T1 breast cancer model.
- 3 February 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1097788
Open AccessSerum amyloid alpha 1-2 are not required for liver inflammation in the 4T1 murine breast cancer model
Cancers induce the production of acute phase proteins such as serum amyloid alpha (SAA) in the liver and cause inflammation in various host organs. Despite the well-known coincidence of acute phase response and inflammation, the direct roles of SAA proteins in inflammation in the cancer context remains incompletely characterized, particularly in vivo. Here, we investigate the in vivo significance of SAA proteins in liver inflammation in the 4T1 murine breast cancer model. 4T1 cancers elevate the expression of SAA1 and SAA2, the two major murine acute phase proteins in the liver. The elevation of Saa1-2 correlates with the up-regulation of immune cell-related genes including neutrophil markers. To examine this correlation in detail, we generate mice that lack Saa1-2 and investigate immune-cell phenotypes. RNA-seq experiments reveal that deletion of Saa1-2 does not strongly affect 4T1-induced activation of immune cell-related genes in the liver. Flow cytometry experiments demonstrate the dispensable roles of SAA1-2 in cancer-dependent neutrophil infiltration to the liver. Consistently, 4T1-induced gene expression changes in bone marrow do not require Saa1-2. This study clarifies the negligible contribution of SAA1-2 proteins in liver inflammation in the 4T1 breast cancer model.